Lecture Notes: Matrix Biology, Articular Cartilage, and Tissue Engineering

Lecture 1: Matrix Biology

Summary:

This lecture introduces the Extracellular Matrix (ECM), detailing its composition, diverse functional properties, and critical roles in both health and disease. The ECM is a complex and dynamic three-dimensional network of molecules that surrounds cells, providing structural support and influencing cellular behavior.

Key Content:

  • ECM Molecules:

    • Collagens: The most abundant proteins in the ECM, with 28 different types forming fibers, networks, and filaments. They are crucial for tissue structure and strength. Collagens are formed from polypeptide alpha-chains creating triple helices. Different tissues have characteristic collagen compositions; for example, dermis and bone are rich in Types I, III, and V, while cartilage contains Types II, IX, and XI.

    • Proteoglycans and Glycosaminoglycans (GAGs): These are the second most abundant ECM molecules. Proteoglycans consist of a core protein with one or more GAG chains (chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate). Hyaluronan is a unique GAG that is non-sulfated and not attached to a protein core; it is vital for joint lubrication. Aggrecan is a major proteoglycan in cartilage, contributing to its compressive stiffness.

    • Elastin: Provides elasticity and resilience to tissues like skin and blood vessels.

    • Laminins and Fibronectin: Glycoproteins involved in cell-cell assembly and binding to other ECM molecules.

    • Matricellular Proteins (Glycoproteins): A diverse family including thrombospondins, SPARC, tenascins, and COMP. They modulate cell function by interacting with cell-surface receptors, proteases, hormones, and structural ECM proteins. They play key roles in tissue remodeling, repair, and various disease states.

    • Enzymes: Matrix Metalloproteinases (MMPs), ADAMs, ADAMTSs, serine proteases, cathepsins, hyaluronidases, and heparanases are ECM components that remodel and degrade the matrix.

  • ECM Functions:

    • Structural Support: The ECM provides the biomechanical properties required by different tissues (e.g., tensile strength in tendons, compressive properties in cartilage, elasticity in skin).

    • Regulation of Cell Behavior: The ECM influences cell proliferation, adhesion, migration, differentiation, inflammation, angiogenesis, wound repair, bone turnover, and cell death. It stores chemical signals like growth factors and cytokines.

  • ECM in Disease:

    • Genetic Disorders: Mutations in ECM genes can lead to conditions like Ehlers-Danlos Syndrome (collagen mutations).

    • Ageing Disorders: Intervertebral disc disease is linked to the loss of GAGs (specifically aggrecan), leading to decreased hydration, reduced compressibility, and increased risk of herniation.

    • Fibrosis: Excessive formation of connective tissue in response to chronic injury, often involving hyperactive TGF-β signaling and uncontrolled ECM secretion by myofibroblasts. Common in pulmonary fibrosis, hepatic fibrosis, and renal scarring.

Current Research & Additional Information:

  • ECM Dynamics: Recent studies emphasize that ECM dynamics are critical for the organization and maintenance of biological form and function. The architecture and mechanical properties of the ECM are crucial in shaping cell identity and phenotype, influencing a wide array of cellular processes.

  • ECM in Disease Pathogenesis: Alterations in ECM composition, structure, and mechanical properties are frequently observed and are key drivers in various diseases like tissue fibrosis, autoimmune/inflammatory conditions, and cancer. This makes the ECM a significant focus for identifying new therapeutic pathways.

  • Cell-ECM Interactions: Understanding the dynamic interplay between cells and their surrounding ECM is a major research challenge. This includes investigating how cells respond to mechanical tension from the ECM (e.g., fiber crosslinking, stiffness) and how this influences signaling pathways (e.g., YAP and ERK1/2 in cancer).

  • Specific ECM Components in Disease: Research is ongoing into the roles of specific ECM proteins in disease. For example, fibronectin's role in cancer progression and nidogen's function as a linker molecule connecting different ECM components are areas of active investigation.

  • ECM in Aging: Studies are exploring how ECM properties like stiffness change with age and how these changes contribute to age-related diseases. For instance, research on lung tissue has shown changes in stiffness at different inflation volumes in aged lungs.

Lecture 2: Articular Cartilage Structure, Function, and Metabolism in Health & Disease

Summary:

This lecture focuses on articular cartilage, covering its morphology, the structure and function of its major ECM components, its biomechanical behavior, homeostasis, and the pathological changes that occur in diseases like osteoarthritis.

Key Content:

  • Morphology of Articular Cartilage:

    • Avascular (no blood vessels), aneural (no nerves), and alymphatic (no lymphatic vessels).

    • Hypocellular (few cells) and lacks a basement membrane.

    • Composed of chondrocytes (resident cells) and an extensive ECM.

    • Zonal Structure:

      • Superficial Zone: Flattened chondrocytes, collagen fibrils parallel to the surface.

      • Middle (Intermediate) Zone: Rounded chondrocytes, collagen fibrils arranged diagonally.

      • Deep Zone: Rounded chondrocytes in columns, collagen fibrils perpendicular to the surface.

      • Calcified Zone: Anchors cartilage to the subchondral bone.

  • Major ECM Molecules in Articular Cartilage:

    • Collagens: Primarily Type II collagen, which forms a framework providing tensile strength. Also contains Types IX and XI, forming heterotypic fibrils. Collagen provides high tensile stiffness but no resistance to compression on its own.

    • Proteoglycans: Aggrecan is the major proteoglycan, responsible for cartilage's compressive stiffness due to the high negative charge of its GAG chains (chondroitin sulfate and keratan sulfate). Aggrecan monomers associate with hyaluronan and link proteins to form large aggregates.

    • Water: Articular cartilage is highly hydrated (65-85% of wet weight).

  • Biomechanical Function:

    • Biphasic Model: Cartilage behaves as a biphasic material with a solid phase (chondrocytes, collagen, proteoglycans) and a fluid phase (water and cations). The solid phase has low permeability, resisting fluid flow, while the fluid phase allows for load transmission through interstitial fluid pressurization. This allows cartilage to withstand and dissipate loads.

    • Lubrication: Lubricin, a glycoprotein found at the articular surface, contributes to the near-frictionless movement of joints.

  • Cartilage Homeostasis:

    • A balance between ECM synthesis and degradation, maintained by chondrocytes.

    • Metalloproteinases (MMPs and ADAMTSs) are the primary enzymes responsible for matrix turnover.

      • Collagenases (MMPs like MMP-1, MMP-13): Degrade triple helical collagens.

      • Gelatinases (MMPs like MMP-2, MMP-9): Degrade denatured collagens.

      • Stromelysins (MMPs like MMP-3, MMP-10): Degrade non-collagenous matrix proteins (but not aggrecan).

      • Aggrecanases (ADAMTS-4, ADAMTS-5): Degrade aggrecan by cleaving it within the interglobular domain (IGD), releasing GAG-attachment domains.

  • Osteoarthritis (OA):

    • A degenerative joint disease characterized by the degradation of articular cartilage.

    • Etiology: Can be primary (idiopathic) or secondary (due to trauma, congenital issues, etc.). Risk factors include age, sex, heredity, obesity, and trauma.

    • Pathophysiology:

      • Chondrocyte metabolism is altered by mechanical forces and inflammatory mediators (e.g., IL-1, TNF-α).

      • Increased synthesis and activation of aggrecanases and MMPs lead to enhanced degradation of aggrecan (early stage) and collagen (late stage).

      • Loss of aggrecan results in reduced compressive properties.

      • Loss of collagen leads to breakdown of the cartilage framework and loss of tensile strength; this is often irreversible.

    • Symptoms: Pain, limited movement, crepitation.

    • Treatments: Steroids, NSAIDs, anti-cytokine antibodies, joint replacement surgery, and emerging cell-based therapies.

Current Research & Additional Information:

  • Tissue Engineering for Cartilage Repair: This field is a key focus, aiming to use cultured cells and scaffold materials to create viable, functional cartilage tissue. Recent advancements highlight the potential of tissue-engineered constructs for OA treatment.

  • Understanding Cartilage Zones: Research emphasizes the importance of the distinct structural and functional roles of each cartilage zone (superficial, middle, deep, calcified) when developing tissue engineering strategies. For example, the superficial zone's lubrication and tensile properties, the middle zone's primary compressive resistance, and the deep zone's load distribution are critical considerations.

  • Biomaterials in Cartilage Engineering: The choice of biomaterials for scaffolds is crucial. They must be biocompatible, support cellular attachment and proliferation, and have degradation kinetics that match neo-cartilage formation (typically maintaining integrity for at least 3-6 months).

  • Metabolic Underpinnings of OA: Emerging research is shifting the understanding of OA from a purely mechanical disease to one that includes metabolic processes. Studies are exploring the "gut-joint axis," involving bile acid metabolism (e.g., GUDCA) and GLP-1 signaling, and how the gut microbiome can influence OA development and progression. This opens new avenues for treatment by targeting these metabolic pathways.

  • Novel OA Treatment Strategies: Beyond traditional methods, research is exploring molecular targeted therapies, biologic treatments (like anti-cytokine antibodies), regenerative medicine approaches, and lifestyle modifications to address the root causes of OA. Acupuncture is also being investigated for its mechanistic insights and potential therapeutic benefits.

Lecture 3: Regenerative Medicine, Tissue Regeneration & Tissue Engineering, Autologous Chondrocyte Implantation

Summary:

This lecture explores the principles of tissue engineering and regenerative medicine as applied to cartilage repair, with a particular focus on Autologous Chondrocyte Implantation (ACI) and its evolution through various generations. It also covers cell sources, scaffolds, and bioactive molecules used in these approaches.

Key Content:

  • Tissue Engineering & Regenerative Medicine:

    • Tissue Engineering: Combines scaffolds, cells, and biologically active molecules to create functional tissues. It has applications in structural replacement, functional replacement (e.g., musculoskeletal tissues), and wound healing.

    • Regenerative Medicine: A broader field that includes tissue engineering and research on self-healing, where the body uses its own systems (sometimes aided by foreign biological material) to recreate cells and rebuild tissues/organs.

    • The Tissue Engineering Triad: Consists of Cell Source, Tissue Architecture (scaffolds, hydrogels, 3D printing), and Niche Properties (growth factors, signaling molecules, nanoparticles, proteins).

  • Key Ingredients for Tissue Engineering:

    • Cell Precursors/Sources:

      • Autologous: Cells from the patient themselves.

      • Allogeneic (Heterologous): Cells from a donor of the same species.

      • Xenogeneic: Cells from a different species.

      • Types: Mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and native tissue cells (e.g., chondrocytes, fibroblasts). These can be derived from various tissues like bone marrow, adipose tissue, umbilical cord, etc..

    • Bioactive Molecules: Growth factors, interleukins, anti-inflammatory molecules, enzymes.

    • Scaffolds: Provide a framework for tissue growth.

      • Natural Products: Purified collagens (Type I), fibronectin, fibrin, hyaluronan, decellularized ECM, silk, plant/animal polysaccharides (cellulose, chitin).

      • Synthetic Biomaterials: Biodegradable polymers like Polylactic acid (PLA) and Polyglycolic acid (PGA), carbon fibers, hydroxyapatite.

      • Composites: Combinations like PLGA/Collagen Type I, PLA/Elastin.

  • Application to Knee Joint Pathology:

    • Knee replacement surgeries are common, and tissue engineering aims to provide treatment options before replacement is necessary.

    • Common knee injuries (ACL tears, meniscal tears, cartilage lesions like Osteochondritis Dissecans) can lead to OA.

    • Osteochondritis Dissecans (OCD): A condition where a fragment of cartilage and subchondral bone separates from the articular surface due to issues like lack of blood supply (osteonecrosis). It's more common in young male athletes (10-20 years old). Symptoms include pain, swelling, locking, and reduced range of motion. Diagnosis is via radiography and MRI.

  • Autologous Chondrocyte Implantation (ACI):

    • First Generation (Brittberg et al., 1994):

      • Harvesting chondrocytes from a non-load-bearing area of the patient's cartilage.

      • Expanding these cells in vitro.

      • Implanting the cultured chondrocytes into the cartilage defect, covered by a periosteal flap (taken from the tibia) sutured and sealed with fibrin glue. The periosteum was thought to provide growth factors and potentially stem cells.

      • Results showed good outcomes in many patients, with biopsies indicating hyaline-like cartilage formation in a majority of cases.

    • Second Generation ACI: Used a bilayer collagen Type I/III membrane scaffold instead of a periosteal flap to simplify surgery and potentially reduce chondrocyte hypertrophy.

    • Third Generation ACI (e.g., MACI - Matrix-Induced ACI): Involved seeding chondrocytes onto biomaterial scaffolds (e.g., hyaluronic acid-based, collagen gels, polymers like BioSeed-C) which are then trimmed and implanted without a periosteal flap. Variations include the use of mesenchymal stem cells.

    • Fourth Generation & Beyond (One-Stage Procedures): Research explores one-stage procedures, for instance, combining mononuclear fraction (MNF) bone marrow cells with primary chondrocytes embedded in fibrin glue, compared to microfracture. Animal models (e.g., goats) have been used to evaluate these newer techniques, assessing macroscopic and microscopic cartilage regeneration using scoring systems like ICRS, O'Driscoll, and Mankin scores. While promising, these techniques require further refinement.

Current Research & Additional Information:

  • Advancements in ACI: Current ACI research focuses on cell-based surgical approaches using advanced biomaterials for both scaffold and scaffold-free implants. The generations of ACI have evolved to simplify procedures, improve cell distribution, and manage different defect sizes.

    • Nose-to-Knee (using nasal septum cartilage): Offers fibrohyaline cartilage but requires nasal septum harvest.

    • Spherox (chondrocyte spheroids): No need for patches, better cell distribution, but may have limitations in maximal age and lateral integration.

    • Cartibeads (chondrocytes in alginate beads): Allows for small cartilage harvest, aims for hyaline cartilage, good integration, but is a two-stage process and currently in clinical trial phases.

  • Osteochondritis Dissecans (OCD) Research:

    • Etiology: Still considered multifactorial, involving genetic predisposition, inflammation, vascular issues, and repetitive microtrauma.

    • Treatment: Conservative treatment (activity restriction, immobilization, physiotherapy) is the first line for younger patients with open growth plates and stable lesions. Surgical options are considered for unstable lesions or failed conservative treatment and include drilling, fragment fixation, or reconstructive procedures like ACI or osteochondral autograft/allograft transfer (OATS). Research continues to optimize both non-operative and surgical treatments and to develop better noninvasive diagnostic tools to predict fragment stability.

  • Synthetic Biomaterials for Cartilage Regeneration:

    • While natural materials (collagen, hyaluronic acid) offer biocompatibility, they often lack mechanical strength. Synthetic polymers (PCL, PLGA) provide mechanical integrity but may lack bioactivity.

    • Innovations: 3D printing, electrospinning, and functionalization of scaffolds with bioactive molecules are advancing scaffold design to enhance tissue regeneration and replicate zonal cartilage architecture.

    • Smart Biomaterials: Future directions include "smart" biomaterials that can respond to stimuli (e.g., electrical, temperature, light, magnetic fields, enzymes) to promote chondrocyte proliferation and differentiation. These materials could convert mechanical energy into electrical signals or release bioactive factors in a controlled manner.

  • Growth Factors in Cartilage Tissue Engineering:

    • Growth factors (e.g., TGF-β superfamily members like BMP-2, BMP-7; IGF-I) are crucial for stimulating ECM synthesis, inducing chondrogenic differentiation of MSCs, and decreasing catabolic effects.

    • BMP-7 is often considered a gold standard due to its ability to decrease catabolic cytokines and stimulate matrix synthesis.

    • Research is ongoing to optimize the delivery and combination of growth factors for effective cartilage repair.

  • Mesenchymal Stem Cells (MSCs) in Cartilage Repair:

    • MSCs are attractive due to their ease of harvest, expansion capability, and multipotency (can differentiate into chondrocytes).

    • MSC-derived Extracellular Vesicles (EVs): Increasing evidence suggests that the regenerative properties of MSCs may be largely mediated by the EVs they secrete. These EVs are rich in bioactive molecules that can promote cell communication, boost growth factor secretion, regulate ECM synthesis/degradation, and modulate inflammation. MSC-EVs offer potential therapeutic benefits without the risks associated with direct MSC transplantation (e.g., low survival rate of transplanted cells).

    • Research is focused on understanding MSC dysfunction during aging and disease (e.g., conversion to adipocytes, reducing the functional pool for bone/cartilage repair) and developing strategies to maintain their regenerative potential.

  • 3D Bioprinting for Cartilage Regeneration:

    • 3D bioprinting allows for the precise fabrication of personalized scaffolds with complex geometries, multi-layered structures, and compositional variations, mimicking native cartilage.

    • Key Factors: Bioink formulation (material properties, cell compatibility), seed cell selection (chondrocytes, MSCs), and printing parameters (porosity, pore size, interconnectivity) are critical. Optimal pore sizes (e.g., 150-300 μm) are needed for nutrient diffusion and cell migration.

    • Challenges & Future Directions: Hurdles for clinical translation include bioink biocompatibility, printing precision, long-term stability of constructs, and vascularization. Future research focuses on advanced printing techniques, novel biomaterials, and optimal cell sources.

Further Reading

Articular cartilage, a complex tissue with limited self-repair capacity, poses significant challenges in tissue engineering (García-Carvajal et al., 2013; Wang & Peng, 2014). Successful cartilage regeneration requires understanding its unique structure, composition, and biomechanical properties (Armiento et al., 2018). Tissue engineering approaches involve three key components: cells, scaffolds, and signaling molecules (Haleem & Chu, 2010). Various biomaterials and fabrication methods have been explored to mimic the native cartilage environment (Melrose et al., 2008; Camarero‐Espinosa et al., 2016). Chondrocyte phenotype maintenance and prevention of hypertrophy are crucial challenges in cartilage engineering (Fosang & Beier, 2011). Recent advancements have shifted focus from treating focal lesions to addressing osteoarthritis, incorporating stem cells and bioactive agents (Vinatier et al., 2016). Despite significant progress, reproducing the complex architecture and functionality of native cartilage remains a major hurdle, with limited clinical translation of current approaches (Armiento et al., 2018; Camarero‐Espinosa et al., 2016).